Anti-CCP Antibody Test
Anti-CCP Antibody Test: Early Diagnosis and Prognosis in Rheumatoid Arthritis
Anti-CCP antibody (anti-cyclic citrullinated peptide) testing is a key tool in the early diagnosis and prognosis of rheumatoid arthritis (RA). Even in the early stages, before clinical symptoms become obvious, anti-CCP can be detected, making it a valuable complement to rheumatoid factor (RF) testing.
What is Anti-CCP Antibody?
CCP stands for cyclic citrullinated peptide, which is a peptide containing citrulline, a modified form of the amino acid arginine.
In RA patients, the immune system mistakenly targets citrullinated proteins, producing anti-CCP antibodies. Notably, these antibodies can appear years before joint inflammation develops, highlighting their role as an early diagnostic marker.
Purpose of the Test
Anti-CCP testing is generally indicated for:
- Early diagnosis of rheumatoid arthritis
- Differentiating RA from nonspecific joint pain
- Supporting diagnosis in RF-negative patients
- Assessing disease prognosis
Test Method: CMIA
The Anti-CCP antibody is commonly measured using CMIA (Chemiluminescent Microparticle Immunoassay), which offers:
- High sensitivity and specificity
- Automated testing capability
- Short analysis time
- Excellent reproducibility
This method is widely used in hospital and reference laboratories.
Reference Range
Reference values may vary by laboratory and reagent.
- < 5.0 U/mL: Negative
- ≥ 5.0 U/mL: Positive
Always interpret results according to the reference range provided by the testing laboratory.
Clinical Significance of Anti-CCP Positivity
Positive anti-CCP results may indicate:
- Rheumatoid arthritis, especially early RA
- RA with rapid joint destruction
- RF-negative RA
Anti-CCP positive patients often have more aggressive disease with a higher risk of joint erosions.
Negative or low anti-CCP levels may indicate:
- Early or atypical RA
- Other inflammatory joint disorders
- Non-RA conditions
Negative results do not completely rule out RA; diagnosis should be made in conjunction with clinical findings, imaging, and other laboratory tests.
Associated Conditions
Anti-CCP antibodies are most specific to RA but can occasionally be seen in:
- Chronic tuberculosis
- Chronic lung disease
- Systemic lupus erythematosus (SLE)
- Sjögren’s syndrome
Other conditions with rare false positives: Behçet’s disease, fibromyalgia, gout, juvenile RA, osteoarthritis. In these cases, titers are usually low.
Sensitivity and Specificity
- Sensitivity: ~70–80%
- Specificity: ~95–98%
Anti-CCP has higher specificity than RF, with fewer false positives. Testing both RF and anti-CCP improves diagnostic accuracy.
Key Points for Interpretation
- Do not rely on anti-CCP alone to diagnose RA
- Consider clinical symptoms, imaging (X-ray, MRI, ultrasound), and other lab tests
- Always refer to the laboratory-specific reference range
- Most useful for diagnosis and prognosis, rather than disease activity monitoring
Summary
Anti-CCP antibody testing is:
- A critical early diagnostic tool for RA
- Highly specific for rheumatoid arthritis
- Especially useful in RF-negative patients
- Integral to current RA diagnostic protocols
References
- Aletaha D, et al. 2010 Rheumatoid arthritis classification criteria. Ann Rheum Dis.
- Nishimura K, et al. Meta-analysis: diagnostic accuracy of anti-CCP antibody. Ann Intern Med.
- van Venrooij WJ, et al. Anti-CCP antibodies in rheumatoid arthritis. Arthritis Res Ther.
- UpToDate. Diagnosis and differential diagnosis of rheumatoid arthritis.
- Tietz Textbook of Clinical Chemistry and Molecular Diagnostics.